Alcon Entered into a Definitive Merger Agreement to Acquire Aerie for ~$770M
Shots:
- Alcon to acquire Aerie for $15.25/share representing a premium of 37% to Aerie’s last closing price with a total deal value of ~$770M. The transaction is expected to close in Q4’22
- The acquisition will advance the diversified portfolio with the addition of R&D capabilities to Alcon’s exisiting commercial expertise in the ophthalmic pharmaceutical eye drop space
- The acquisition will add Aerie’s Rocklatan (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% and Rhopressa (netarsudil ophthalmic solution) 0.02%, AR-15512 along with a pipeline of multiple clinical and preclinical ophthalmic pharmaceutical product candidates to Alcon’s portfolio
Ref: Businesswire | Image: Alcon
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
